Title: Blocking AMPK?1 myristoylation enhances AMPK activity and protects mice from high-fat diet-induced obesity and hepatic steatosis
Authors: Neopane, K
Kozlov, N
Negoita, F
Murray-Segal, L
Brink, R
Hoque, A
Ovens, AJ
Tjin, G
McAloon, LM
Yu, DY
Ling, NXY
Sanders, MJ
Oakhill, JS
Scott, JW
Steinberg, GR
Loh, K
Kemp, BE
Sakamoto, K
Galic, S
Issue Year: 2022
Publisher CELL PRESS
Series CELL REPORTS:
Abstract AMP-activated protein kinase (AMPK) is a master regulator of cellular energy homeostasis and a therapeutic target for metabolic diseases. Co/post-translational N-myristoylation of glycine-2 (Gly2) of the AMPK 0 subunit has been suggested to regulate the distribution of the kinase between the cytosol and membranes through a myristoyl switchmechanism. However, the relevance of AMPK myristoylation for metabolic signaling in cells and in vivo is unclear. Here, we generated knockin mice with a Gly2-to-alanine point mutation of AMPK01 (01-G2A). We demonstrate that non-myristoylated AMPK01 has reduced stability but is associated with increased kinase activity and phosphorylation of the Thr172 activation site in the AMPK a subunit. Using proximity ligation assays, we show that loss of 01 myristoylation impedes colocalization of the phosphatase PPM1A/B with AMPK in cells. Mice carrying the 01-G2A mutation have improved metabolic health with reduced adiposity, hepatic lipid accumulation, and insulin resistance under conditions of high-fat diet-induced obesity.
URI: https://publications.svi.edu.au/publications/8890
Other Identifiers 10.1016/j.celrep.2022.111862
Publication type Article